Victory Capital Management
PLX icon

Victory Capital Management’s Protalix BioTherapeutics PLX Stock Holding History

Victory Capital Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-5,140
Closed -$12K – 3070
2020
Q1 		$12K Buy
+5,140
New +$17K ﹤0.01% 3257
2019
Q4 		– Sell
-2,670
Closed -$5K – 3093
2019
Q3 		$5K Buy
+2,670
New +$7.97K ﹤0.01% 3458

Other funds holding PLX

HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Victory Capital Management's PLX Position: Q2 2020 in Review

Victory Capital Management sold out of Protalix BioTherapeutics (PLX) in Q2 2020, closing a stake of 5,140 shares — an estimated $12K sold.

Victory Capital Management first reported a position in PLX in Q3 2019 and held it in 2 quarters. The position peaked at $12K in Q1 2020. 28 funds tracked by Wall St. Rank hold PLX as of Q2 2020.

  • Victory Capital Management reported no remaining Protalix BioTherapeutics position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 5,140 Protalix BioTherapeutics shares in Q2 2020, an estimated $12K.
  • Victory Capital Management first reported a position in Protalix BioTherapeutics in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Protalix BioTherapeutics position peaked at $12K in Q1 2020.
  • 28 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.